The next (re)generation

Regenerative medicine is continuing to draw believers from the scientific and investment communities, who are putting stock in the technology’s potential to create transformational therapies. But while there’s plenty of enthusiasm for the scientific progress, stakeholders fear more clinical failures and company closures could send investors and regulators running.

Consequently, regenerative medicine appears to be heading to a Catch-22 in which stakeholders want industry to embrace the risks and drive progress, but fear too many failures might damage the field long term...